Integrating immunotherapy into chemotherapy: real-world efficacy of GEMOX plus Tislelizumab in advanced gallbladder cancer

This study aimed to evaluate the efficacy and prognostic factors of GEMOX (gemcitabine and oxaliplatin) combined with Tislelizumab in patients with advanced Gallbladder cancer (GBC). 150 patients with stage III-IV GBC were divided into two groups: 88 received GEMOX alone, and 62 received GEMOX combined with Tislelizumab. Clinical characteristics, treatment responses, progression-free survival (PFS), overall survival (OS) and adverse events were analysed. The combination group showed improved median OS (13.35 vs. 10.26 months, HR = 0.530, 95% CI: 0.357-0.786) and PFS (7.28 vs. 5.18 months, HR = 0.393, 95% CI: 0.278-0.555). The disease control rate (DCR) and objective response rate (ORR) were significantly higher in the combination group (DCR: 83.87% vs. 67.05%, P = 0.021; ORR: 40.32% vs. 20.45%, P = 0.008). Multivariate analysis identified TNM stage, CA19-9 status, CPS score, tumour diameter, and lesion multiplicity as independent prognostic factors for OS. GEMOX combined with Tislelizumab may improve survival outcomes in patients with advanced GBC.